Researchers Developed New Peptide Bicyclization Method
A novel chemical strategy enables the rapid screening of bicyclic peptides to target therapeutic proteins like PD-1.
Updated on Oct. 3, 2026 in Chemistry
Researchers have developed a new method called PReP-Bicyc to create bicyclic peptides, which are molecules with enhanced conformational stability. This research-stage approach facilitates the screening of bicyclic ligands against targets like the programmed cell death protein 1 (PD-1).
Why it matters
Peptide bicycles offer superior structural rigidity compared to linear counterparts, but their creation within phage-displayed libraries—a common method for discovering drug candidates—has historically been challenging. This technique overcomes those synthesis limitations by allowing the formation of complex structures under mild conditions that preserve phage viability.
The PReP-Bicyc method utilizes 4,6-dichloropyrimidine-2-carbonitrile as a linker to achieve binding affinities of approximately 400 nM. This approach demonstrates a performance improvement over traditional cyclization constraints that often compromise phage display library integrity.
The players
PReP-Bicyc
A newly developed chemical method for synthesizing bicyclic peptides within phage-displayed libraries.
The details
The method uses the linker 4,6-DCCPm to react with an N-terminal cysteine—a sulfur-containing amino acid—through a process called thiazoline formation. This triggers a proximity-driven intramolecular thiol arylation, where the linker joins two internal cysteines to lock the peptide into a bicyclic shape. By performing these reactions under mild conditions, the researchers maintain the integrity of the phage, a virus that infects bacteria and acts as a delivery vehicle for peptide display.
Timeline
October 3, 2026: The peer-reviewed research article detailing the PReP-Bicyc approach was published.
The Tech Race
This development addresses a persistent bottleneck in phage-displayed library screening by simplifying the synthesis of structurally constrained peptides. It positions the technique as a viable alternative to existing cyclization protocols that often struggle to maintain the stability of display organisms during complex chemical reactions.
This laboratory-stage discovery currently serves as a tool for drug discovery researchers working on protein-targeting therapies. Further development will be required to determine if this synthesis method can be scaled for the clinical production of targeted inhibitors for PD-1-expressing cells.
The takeaway
The PReP-Bicyc method significantly lowers the chemical barrier to generating stable, bicyclic peptide ligands for therapeutic protein targets. Researchers and drug developers should monitor subsequent studies to see if these ligands demonstrate potency in cell-based assays beyond initial PD-1 binding results.
Further reading
For more developments in structural synthesis and molecular design, visit the Chemistry section.
More information
View the complete peer-reviewed research article for detailed chemical protocols.
